High Fibrinogen Levels: Causes, Health Risks, and Treatment

Fibrinogen is a protein made by the liver that helps blood clot, and when its levels climb too high, it shifts from being protective to being a genuine cardiovascular threat. Normal plasma fibrinogen sits roughly between 200 and 400 mg/dL, and levels that persistently exceed that range have been linked to heart attacks, strokes, and pulmonary embolism. Because fibrinogen is also an acute-phase protein, meaning it surges during inflammation, teasing apart what is cause and what is consequence of disease turns out to be one of the trickier problems in vascular medicine.

What Fibrinogen Actually Does

Fibrinogen circulates in the blood as a large molecule made of three pairs of protein chains. During the final step of the clotting cascade, an enzyme called thrombin clips small pieces off fibrinogen, converting it into fibrin monomers. Those monomers then link together into a mesh that traps platelets and red blood cells, forming the structural scaffold of a blood clot.¹ This is exactly what you want when you cut your finger. The trouble starts when fibrinogen levels are chronically elevated: more raw material for clots means clots can form faster, grow larger, and resist being dissolved.

Fibrinogen also promotes red blood cell clumping. Higher concentrations cause red cells to stack together more readily, which thickens the blood and slows flow through small vessels.² That sluggish flow can itself promote clot formation, setting up a feedback loop where high fibrinogen raises blood viscosity, which in turn creates the stagnant conditions that encourage even more clotting.

Why Fibrinogen Goes Up

Elevated fibrinogen almost always traces back to one or more of three broad categories: ongoing inflammation, metabolic conditions, or genetics. In practice, many people have a mix of all three.

Inflammation and Acute-Phase Response

Fibrinogen is one of the liver’s go-to products when the body senses tissue damage or infection. The signaling molecule interleukin-6, a cornerstone of the inflammatory response, directly ramps up fibrinogen gene activity in liver cells.³ In one study of fibrinogen gene variants, interleukin-6 produced roughly a fourfold increase in one fibrinogen chain and an eightfold increase in another, showing that the inflammatory signal doesn’t just nudge production — it can multiply it dramatically.⁴ Any condition that keeps interleukin-6 and related cytokines elevated — rheumatoid arthritis, chronic infections, inflammatory bowel disease, even severe tissue injury from trauma — will tend to push fibrinogen upward as part of that same acute-phase machinery.⁵

Obesity, Metabolic Syndrome, and Diabetes

Excess body fat is one of the most common reasons fibrinogen stays chronically elevated in otherwise “healthy” people. In a population-level study, people with metabolic syndrome had average fibrinogen levels around 300 mg/dL compared with roughly 285 mg/dL in those without it, and the prevalence of clearly elevated fibrinogen (above 350 mg/dL) more than doubled as the number of metabolic abnormalities increased.⁶ The relationship starts early: overweight children already show higher fibrinogen than normal-weight peers, and the association tracks with BMI independently of insulin resistance.⁷

Fat tissue is metabolically active and secretes inflammatory molecules, so at least some of the fibrinogen rise in obesity is driven by the same interleukin-6 pathway described above. But the association between fibrinogen and insulin levels appears to hold even after accounting for inflammation markers, suggesting that metabolic disruption contributes through additional routes that researchers are still working out.

Genetics

Your baseline fibrinogen level has a heritable component. One of the best-studied genetic variants involves a change at position 455 in the beta-fibrinogen gene. People carrying the A allele at that site tend to have higher fibrinogen than those with the G allele, and the effect is most pronounced in younger, non-smoking individuals — in one study, men under 55 with the variant had fibrinogen levels about 12% higher than their peers.⁸ A separate study in patients with atrial fibrillation confirmed a dose-response pattern: each additional A allele nudged fibrinogen higher, with the AA genotype group averaging about 3.7 mg/dL compared with roughly 2.9 mg/dL in the GG group.⁹

Genetics rarely act alone. Smoking, age, and obesity all interact with these gene variants to amplify or mask their effects. In the study of the G/A-455 polymorphism, the genetic influence on fibrinogen essentially disappeared in current smokers, likely because smoking itself drives fibrinogen so high that the additional genetic bump gets lost in the noise.⁸

Age, Menopause, and Hormones

Fibrinogen tends to drift upward with age in both sexes. In women, menopause brings a distinct additional rise. Data from the Postmenopausal Estrogen/Progestin Interventions (PEPI) study found that fibrinogen increased with age even after controlling for other variables, and women who had never used hormone replacement therapy had higher fibrinogen than those who had.¹⁰ A separate analysis confirmed that postmenopausal women had higher fibrinogen than premenopausal women, and those on hormone replacement therapy had lower levels, though the authors noted that selection bias could account for part of that difference.¹¹ The practical takeaway is that a “normal” fibrinogen result at age 40 may look different from a “normal” result at age 65, and clinicians should interpret the number in context.

Cardiovascular Risks

The connection between high fibrinogen and heart disease has been studied for decades. Elevated levels promote atherosclerosis through several overlapping mechanisms: fibrinogen accumulates within arterial plaques, damages the inner lining of blood vessels, and triggers platelet activation, all of which accelerate plaque growth and make plaques less stable.¹² When a plaque does rupture, the excess fibrinogen provides abundant material for a clot to form rapidly at the rupture site, potentially blocking the artery and causing a heart attack.¹³

Whether fibrinogen is a direct cause of cardiovascular events or merely a marker of the underlying inflammation that drives them remains somewhat debated. However, recent genetic approaches are tipping the balance toward causality, at least for stroke. A Mendelian randomization study — which uses naturally occurring genetic variants as a stand-in for a controlled experiment — found that each 1 g/L increase in genetically predicted fibrinogen roughly doubled the risk of ischemic stroke.¹⁴ A meta-analysis of observational data tells a consistent story, estimating that elevated fibrinogen was associated with about a 47% higher odds of ischemic stroke.¹⁵ The association holds in younger adults too, not just the elderly.¹⁶

Risks Beyond the Heart and Brain

Pulmonary Embolism

High fibrinogen raises the risk of pulmonary embolism. People in the top fifth of fibrinogen levels (roughly 4.6 g/L or higher) had about twice the odds of a pulmonary embolism compared with those in the lowest fifth (3.0 g/L or less) after adjusting for other risk factors.¹⁷ An unexpected finding from the same large study was that fibrinogen had no clear link to deep vein thrombosis on its own. In other words, high fibrinogen seems specifically tied to clots that travel to the lungs rather than clots that stay in the leg veins. Researchers are still sorting out why, but one theory involves the role of fibrinogen-driven red cell aggregation in creating conditions that preferentially dislodge existing clots and send them toward the pulmonary circulation.

Cancer Prognosis

High fibrinogen levels frequently show up in people with cancer, and the relationship appears to go beyond just “cancer causes inflammation which raises fibrinogen.” In gastric cancer, elevated fibrinogen thickens the blood and makes it easier for tumor cells to travel through the bloodstream, potentially increasing the risk of metastasis. Abnormally high fibrinogen can also disrupt the normal system for dissolving clots, further enabling cancer spread.¹⁸ While lowering fibrinogen is not an established cancer treatment, high levels at the time of diagnosis are increasingly used as a prognostic marker, signaling worse outcomes across several tumor types.

Alzheimer’s Disease

A more recently explored connection involves the brain. Fibrinogen that leaks across a weakened blood-brain barrier can bind to amyloid-beta, the protein that accumulates in Alzheimer’s disease. That binding appears to create fibrin deposits that are abnormally resistant to breakdown, which may restrict blood flow in small brain vessels, amplify neuroinflammation, and contribute to neurodegeneration.¹⁹ This research is still in relatively early stages, and nobody is yet recommending fibrinogen-lowering therapy for dementia prevention. But it illustrates that the consequences of chronically elevated fibrinogen may reach far beyond the cardiovascular system.

How Fibrinogen Is Measured

If your doctor orders a fibrinogen test, the lab will almost certainly run a Clauss assay. A diluted sample of your plasma gets exposed to a high concentration of thrombin, and the lab measures how quickly a clot forms. That clotting time is then converted into a fibrinogen concentration using a standard reference curve.²⁰ The Clauss assay is a functional test, meaning it measures fibrinogen’s actual ability to form a clot, not just how much of the protein is floating around.

Some labs instead derive a fibrinogen estimate from the prothrombin time test, which is a routine clotting test run on many blood samples. This PT-derived method correlates well with the total amount of fibrinogen protein present but doesn’t always reflect how well that fibrinogen is working.²¹ In rare conditions where fibrinogen is structurally abnormal (dysfibrinogenemia), the two methods can give strikingly different results: the PT-derived test may say your fibrinogen is normal, while the Clauss test reveals it’s functionally impaired. If a clinical scenario suggests a clotting problem and the numbers don’t match up, this discrepancy is a clue that something may be wrong with the fibrinogen itself, not just its quantity.

Lowering Fibrinogen Through Lifestyle

The single most effective non-drug approach to bringing fibrinogen down is regular aerobic exercise. A review of longitudinal studies found that sustained endurance exercise over several months reduced fibrinogen by an average of about 0.4 g/L, which the authors estimated would translate to a meaningful reduction in coronary heart disease risk.²² That review went so far as to call exercise “the most practicable approach known to date” for lowering fibrinogen, which is a strong endorsement given how few drug options reliably accomplish the same thing.

Weight loss also helps, especially in people who are significantly overweight and already have high fibrinogen. In a study of 60 obese patients who followed a calorie-restricted diet for about ten months and lost an average of roughly 17 kg, fibrinogen dropped along with blood pressure, triglycerides, and blood sugar. The effect was most pronounced in those who started with the highest fibrinogen levels and achieved the greatest weight reduction.²³ Whether the fibrinogen drop comes from reduced inflammation, improved insulin sensitivity, or both is hard to untangle, but from a practical standpoint, the mechanism matters less than the result.

Smoking cessation is another lever. Smoking independently raises fibrinogen, and quitting brings it back down over time. Combined with the fact that smoking swamps even the genetic determinants of fibrinogen levels, stopping is one of the highest-impact changes a person can make.

Drug Treatments That Affect Fibrinogen

No drug is currently approved specifically to lower fibrinogen. But several existing medications lower it as a side effect, and in some cases that effect is clinically meaningful.

Fibrates — drugs primarily prescribed to manage high triglycerides — are the most consistently effective fibrinogen-lowering medications available. A meta-analysis comparing fibrates head-to-head with statins found that fibrates reduced fibrinogen by an average of about 40 mg/dL more than statins did. Fenofibrate was the most potent, with an estimated reduction of roughly 44 mg/dL, while bezafibrate lowered levels by about 24 mg/dL.²⁴ Older literature has reported bezafibrate reducing elevated fibrinogen by as much as 40% in some patients, and ticlopidine (an antiplatelet agent) lowering it by about 15%.

The picture with statins is murkier. In the same pharmacoepidemiological analysis, fibrinogen actually rose slightly after statin therapy on average, despite statins’ known anti-inflammatory properties.²⁵ However, at least one study of high-dose atorvastatin in patients with very high cholesterol saw fibrinogen drop by about 18% after six months of treatment.²⁶ The discrepancy may come down to dose, patient population, and how inflamed someone was to begin with. For people whose primary concern is fibrinogen rather than LDL cholesterol, fibrates are the stronger tool.

A Combined Approach in Practice

A randomized clinical trial tested an intensive lifestyle intervention in primary-care patients who had elevated fibrinogen but no prior cardiovascular event. The intervention combined smoking cessation support, dietary counseling, and structured exercise. The intensive group achieved an average fibrinogen reduction of about 31 mg/dL, which the investigators estimated would shift some patients from a high-risk category to moderate risk on standard cardiovascular assessment scales.²⁷ That may sound modest, but the shift in risk category matters for deciding whether someone needs medication or can manage with lifestyle changes alone. It also reinforces that fibrinogen is not a number you can simply pop a pill for — the most effective strategies involve sustained behavioral changes, sometimes supplemented by medications that address the underlying condition driving fibrinogen up.

When Fibrinogen Rises During Pregnancy

Fibrinogen naturally climbs during pregnancy, sometimes reaching levels that would be considered clearly abnormal in a non-pregnant person. The body does this for good reason: childbirth involves significant blood loss, and higher fibrinogen prepares the clotting system to respond quickly. But the rise also increases blood viscosity. Research from the early 1980s showed that plasma from pregnant women causes red blood cells to aggregate more than usual, with the effect clearly driven by plasma factors rather than changes in the cells themselves.²⁸ That increased stickiness contributes to the well-known elevated risk of blood clots during and shortly after pregnancy. Clinicians generally expect fibrinogen to be high during pregnancy and do not treat it the same way they would treat elevated levels outside of pregnancy. The level should return to normal in the weeks after delivery.

Why Fibrinogen Is Not Routinely Screened

Given everything above, you might wonder why fibrinogen testing isn’t part of standard annual bloodwork. Part of the answer is that fibrinogen fluctuates a lot in response to short-term events. A single blood draw after a bad cold, a minor injury, or a stressful week could show an elevated level that means nothing about your long-term cardiovascular risk. To be clinically useful, fibrinogen would ideally be measured multiple times under stable conditions, and that adds cost and complexity. Another issue is that even though high fibrinogen clearly correlates with worse cardiovascular outcomes, there is no large randomized trial showing that specifically targeting fibrinogen — independent of managing the conditions that raise it — prevents heart attacks or strokes. Most guidelines recommend addressing the underlying drivers (inflammation, obesity, smoking, metabolic syndrome) rather than chasing the fibrinogen number itself. If your doctor does order a fibrinogen level, it is usually because they suspect a clotting disorder, are evaluating unexplained inflammation, or are monitoring a known condition rather than screening the general population.